Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why is it bad? It’s a deal. Take what you can get. Live to fight another day. Also, don’t forget 6% royalties. And this is JUST for UP/UPS. We still have several B platforms in play as well as K.
Just because it hasn’t happened yet within an assumed timespan doesn’t mean it was a lie. I think that is the problem with investing, especially on the OTC. People assume things will occur at a certain date or month or year and when it doesn’t, they become disillusioned and angry and spout off “the company lied” and “this is a scam.” I think people were placing Sept 30th as this magical date where all their dreams will come true. Could it still happen by that date...sure! Could that date pass and nothing has changed...absolutely! You either think the stock will be successful over time or you don’t. Investing is that simple. But if you invest trying to time certain events or announcements, that usually ends in disappointment. You either think this stock will go to $0 or back to all time highs or higher. We can tell which side of the coin certain individuals are based on their posts. But if you bought this stock recently thinking you were going to own an island by the end of year, investing is probably not your thing. But if you bought several years ago and have been patiently waiting and didn’t invest more than you are willing to lose...what is a couple more months to see if the company delivers?
Go IPIX!
Ocata (OCAT)
13G out.
Both Aruda and his wife have sold 184,400 shares each since last 13G filing on 4/28/17. Each still own almost 7.32 million shares.
Don't post much. But wanted to say Peace out! This message board has become an abyss of negativity, fud, whining, and factual inaccuracies. Responding to it is futile and pointless since the authors refuse to be swayed to change their tune or motives. I understand you do it for potentially new investors doing research. But way too much noise lately and frankly coming to this board has lost its fun and excitement. Too bad because I enjoyed posts from some of the true longs. Still long and strong and one day when we have our day in the sun and shut up these yahoos, I'll be back.
Go IPIX!
Innovation Pharmaceuticals to Discuss Recent Positive Clinical Results in IBD and Upcoming Milestones in Oral Mucositis and Psoriasis Trials at BioCentury’s “NewsMakers” Conference
August 15, 2017 07:00 ET | Source: Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that the Company will present a corporate overview at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel in New York, NY.
The presentation is scheduled for 2:30 pm (EDT) on Friday, September 8, 2017 in Room 302/303. A corresponding presentation slide deck will be made available under the Events and Presentations section of the Company website following the event.
“BioCentury’s NewsMakers conference is a great opportunity for us to share our recent positive clinical trial results regarding Brilacidin treatment of ulcerative proctitis/proctosigmoiditis (two types of Inflammatory Bowel Disease; IBD). We will also highlight the major events upcoming for us in the fourth quarter, namely anticipated completion of our Phase 2 trials of Brilacidin-OM for oral mucositis and Prurisol for psoriasis,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “These trials will provide perspectives as to how our drug candidates might progress toward tremendous market opportunities, as there is a need for a preventative medicine for oral mucositis and a new oral drug for psoriasis to challenge the current treatments. BioCentury established this conference as a premier venue for highlighting companies with upcoming milestones by putting them in front of analysts and institutional money managers. With next steps for our IBD program in planning and the conclusions of the Brilacidin-OM and Prurisol studies approaching, the event is particularly relevant for us in keeping the investment community current in our drug development programs.”
Alerts
Sign-up for Innovation Pharmaceutical email alerts is available at:
http://www.ipharminc.com/email-alerts
About the Company
Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals Inc. (IPI), formerly Cellceutix Corporation, is publicly-traded under the company symbol “IPIX”. The Company is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. The Company believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. The Company’s Psoriasis drug candidate Prurisol completed a Phase 2 trial and a Phase 2b study is ongoing. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. The Company’s anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and the Company has commenced a Phase 2 study in Ovarian Cancer. In the laboratory, Kevetrin has been shown to modulate p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Brilacidin, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative Oral Mucositis (OM) by more than 94% compared to placebo. The Company is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of OM in patients with Head and Neck Cancer; interim results have shown a marked reduction in the incidence of severe OM (WHO Grade ≥ 3). The Company’s lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (“superbugs”). Topline results are now available for the Phase 2, open label Proof-of-Concept trial, treating patients with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD). The Company has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Company website at www.IPharmInc.com.
Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning projected timelines for the initiation and completion of clinical trials, our future drug development plans, other statements regarding future product developments, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause the Company’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Company’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that the Company’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in the Company’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
INVESTOR AND MEDIA CONTACT
Innovation Pharmaceuticals
Leo Ehrlich
info@ipharminc.com
Related Articles
More articles issued by Innovation Pharmaceuticals, Inc.
More articles related to:
Health
Profile
Innovation Pharmaceuticals, Inc.
Subscribe via RSS
Subscribe via ATOM
Javascript
Beverly, Massachusetts, UNITED STATES
http://www.cellceutix.com
Contact Data
INVESTOR AND MEDIA CONTACT
Innovation Pharmaceuticals
Leo Ehrlich
info@ipharminc.com
Contact
Newswire Distribution Network & Management
Home
Newsroom
RSS Feeds
Legal
Contact Us
ABOUT US
GlobeNewswire, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
© 2017 GlobeNewswire, Inc. All Rights Reserved.
This is from the earnings conference call transcript...
We still have millions of dollars available for our equity line and really our goal is we should accomplish several developmental milestones over the coming months. With strong clinical data, I wouldn't anticipate any difficulties in securing additional capital on favorable terms.
However, as we said, our goal is partnerships. If achieved that's game changing with respect to expeditious drug developments and infusions of capital. So, let's say ultimately, we're working vigilantly on maturing the negotiations towards landing a partner, but we're diligent on all the little capital needs that we always have to try to make sure there's enough in the bank to keep going. I hope that answers your question.
More contracts awarded!!
http://ir.intercloudsys.com/press-releases/detail/897
Latest 10Q...
The number of shares outstanding of each of the issuer’s classes of common equity, as of May 1, 2017 is as follows:
Common Stock Class A, $0.0001 par value
131,380,668
Don't know your definition of crazy, but check out CPXX
Here's What InterCloud Systems Inc (OTCMKTS:ICLD)'s Earnings Report Really Means
By Chris Sandburg / in Earnings, Momentum & Growth, Momentum Stocks, Stocks, Tech / on Monday, 15 May 2017 12:54 PM / 0 Comment / 420 views
InterCloud Systems Inc (OTCMKTS:ICLD) spiked to nearly $0.10 a share back in Mid-March, but across the subsequent eight weeks, declined to circa $0.03 a piece.
Management just put out first quarter financials and while it’s not a faultless report, the numbers indicate that things are moving in the right direction. If the company can stay its course, we think there’s plenty of room for upside revaluation back towards, and potentially in excess of, the March highs.
Here is what the numbers show and where they fit into the InterCloud picture.
For those new to the stock, InterCloud is a technology play with a core focus on offering network and data solutions to commercial clients. As we noted last time, two core elements of its offerings represent areas of considerable growth potential – software-defined networking (SDN), and network function virtualization (NFV). We aren’t going to go into too much detail into these technologies this time around (readers looking to catch up can do so here), but by way of a brief overview, they allow for the separation of main network functions from the software that’s used to run them. This separation is becoming increasingly important as commercial entities shift towards cloud networks and we think InterCloud is well-positioned to capitalize on said shift going forward.
Looking at the numbers, the company reported revenues for the first quarter 2017 at $14 million – a 21% decline on the $17.6 million recorded during the first quarter of 2016. Gross profit also declined from $4.4 million in 2016 (first quarter) to $3.4 million during the quarter just gone. Net loss increased from $4.3 million to $14.2 million, but this was primarily attributable to asset impairment charges of $3.9 million and a change in fair value of derivative instruments of $5.3 million; in other words, one-off costs contributed to the difference between the bottom line figures, making the latest number not particularly useful from a forecasting perspective.
Looking at the first couple of figures, initial interpretation is not that great. Declining revenues and gross profit wouldn’t normally be seen as an indication of strength. In this instance, however, things are a little different. Management has spent the last 12 months trying to implement a restructuring plan, as part of which the company is essentially shrinking towards becoming cash positive. As noted in the latest release, and when compared to this same period a year earlier, salaries and wages have been reduced by 20% and SG&A was cut by approximately 10%. Further, the company reduced senior secured debt by $4.2 million and reduced subordinated debt by $4.1 million. This equates to a total quarterly debt reduction of more than $8.3 million. That’s a big deal. The debt element of its balance sheet has long weighed on InterCloud’s potential for value appreciation, and the lifting of this weight should translate to increased speculative volume going forward.
So what’s next?
Well, we want to see more of the same. As mentioned, it is all about the company managing to stay its course and management successfully implementing the restructuring efforts that are going to turn the company around. For us, there’s much more value in being a cash flow positive company, albeit a smaller one, than there is in being a bloated company that can’t meet its own operational expenses. While the topline figures may not make for great reading, therefore, and the headline dip in operational activity might – to some investors – imply a weakening company, we think the opposite is true.
We also think that current shareholders would agree with us.
As indicative of future strength, therefore, we’re actually looking for a continued dip in the headline metrics. Once the foundations are in place, meaning once the company has unloaded non-core assets, trimmed down its staff and is cash flow positive (and we’re looking at a timeline of somewhere around early 2018 for this), management can then start working on a controlled expansion.
Keep in mind that this is a long-term thesis. This company may well dip near term as markets respond to what seems like a contraction. Any dip, however, could be a nice opportunity to pick up cheap shares.
We will be updating our subscribers as soon as we know more. For the latest updates on ICLD, sign up below!
Sign up for next microcap runner ahead of the crowd.
Submit
Disclosure: We have no position in ICLD and have not been compensated for this article.
Presentation is up...
And I was disagreeing with Amatuer, not you Kahuna.
Have to disagree. He might have 100% confidence in the company and drugs, but a lot of variables out of his control...FDA, trial progress, FUD articles, etc. Nothing wrong with taking some risk off the table. I just did with Tesla (keeping some shares). Does that mean I have no confidence in that stock anymore? Absolutely not. The fact remains you have no idea why someone sells. Stating he did so because lack of confidence is negatively biased. There are two views of this stock...negative and positive. And those views will not be changed no matter. I think we know which one you have. My view is I have no problem with people selling. Each is own. Doesn't change my long term vision of the company.
Now why can't this happen with CTIX...
this stock was up 78% today!
https://psoriasisnewstoday.com/2017/04/11/owc-cannabinoid-based-topical-cream-psoriasis/
Don Seiffert
Managing Editor
dseiffert@bizjournals.com
Maybe came from this...
Cellceutix: Financing Partners Arrested For Alleged Ponzi Scheme, Company Faces Risk Of Death Spiral Liquidity Crunch $CTIX
http://www.seekingalpha.com/article/4037325
AF is already tweeting a negative spin on the release.
Down 0.23% is ugly?
Actually, he would be right if price drops to 50 cents and then jumps back to $1.50!
Cellceutix Novel Anti-Inflammatory Phase 2 Drug Candidate Brilacidin Builds Momentum Across Multiple Clinical Indications
GlobeNewswire•October 26, 2016
BEVERLY, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, is pleased to announce today that the favorable pharmacokinetic profile of Brilacidin in Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS) supports Brilacidin’s potential in treating patients in our ongoing, FDA Fast Track-designated, Phase 2 study of Brilacidin-OM as an oral rinse to attenuate Oral Mucositis in patients with Head and Neck Cancer receiving chemoradiation.
As previously reported, initial interim results in UP/UPS, a type of Inflammatory Bowel Disease (IBD), revealed clinically meaningful improvements in the first cohort of four patients treated with Brilacidin at the lowest dose (50mg). Localized treatment with Brilacidin at 50mg by daily enema administration for 42 days produced clinical benefit without measurable plasma drug levels. More specifically, measurements of concentrations of Brilacidin in plasma showed all levels, across all time points, to be below the lower limit of quantification (i.e., <100 ng/mL), which is consistent with limited systemic exposure from administration per rectum by enema.
These data suggest that other inflammatory conditions may, likewise, be treated locally and efficaciously with Brilacidin without significant systemic absorption, better ensuring a safe and well-tolerated therapeutic profile. Given Brilacidin’s low level of systemic exposure, moderate-to-high dosing of the drug by topical application to the skin might also be supported in treating various dermatology disorders and conditions.
Additional reporting of results from the Phase 2 Proof-of-Concept (PoC) clinical trial of Brilacidin-UP/UPS is anticipated over the coming months, as is an interim analysis in the first half of 2017 of the Phase 2 clinical trial of Brilacidin-Oral Mucositis.
Read More
More so for SDRL it seems...up 25%!
The future dividend stability for SDLP seems to be in question, thus limiting the share price action today. Only reason I can think of why not participating in the double digit appreciation.
Vitae Acquisition & Cellceutix Provides Business Update and Timeline of Upcoming Milestone
View it in your browser.
September 15, 2016
My Fellow Cellceutix Shareholders,
Yesterday, news was released that Allergan plc (NYSE: AGN) has agreed to acquire Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE) for $21.00 in cash (a 159% premium to the value of VTAE shares on Tuesday) for a total transaction value of approximately $639 million. First off, we’d like to congratulate Vitae on the acquisition offer.
With the acquisition, Allergan would take control of Vitae’s two clinical drug candidates, VTP-43742, an oral therapy for psoriasis and other autoimmune disorders, and VTP-38543, a drug candidate for the treatment of atopic dermatitis (eczema). The former has completed a Phase 2a proof-of-concept trial in patients with moderate to severe psoriasis and Vitae plans to initiate a 16-week Phase 2b trial during the fourth quarter. VTP-38543 is currently in a Phase 2a proof-of-concept trial evaluating treatment in patients with mild to moderate eczema.
I share this with you because it exemplifies the premium that the industry is placing on new, oral psoriasis drugs, even those in mid-stage development. I’m not in the business of analysis, but it seems to me that Allergan values VTP-43742 at more than our total market capitalization. As such, we see a tremendous market opportunity with Prurisol and greatly look forward to initiating our Phase 2b trial in patients with moderate to severe psoriasis with emphasis on the Psoriasis Area and Severity Index (PASI). We’ve just advanced substantial start-up payments to vendors towards the trial, an action that we feel will continue to grow shareholder value.
I wish to point out that Dr. Bertolino is now introducing Prurisol to large pharmas, most of which are embracing it for the first time. We believe that the path to a large financial deal is generation of comparably encouraging data in Phase 2b as recently seen in our completed Phase 2a trial.
Prurisol, our oral drug in development for treating psoriasis
We have completed the Phase 2a trial evaluating multiple dosing levels of Prurisol in mild to moderate psoriasis patients and the trial successfully met its primary endpoint. More details on the trial are provided at: http://cellceutix.com/cellceutix-phase-2-trial-of-prurisol-for-mild-to-moderate-psoriasis-meets-primary-endpoint/#sthash.s7T0r6y3.DKbIw1B9.dpbs.
In our Phase 2b trial, which we anticipate to commence in the fourth quarter, we are increasing the dosing levels of Prurisol to 300mg and 400mg in the treatment arms, compared to the highest dosing of 200mg in the completed study. Further, we will be treating patients with moderate to severe psoriasis and focus on PASI scoring, in order to provide appropriate data for Phase 3 planning. It is our belief that the higher dosing levels in patients with more severe psoriasis will deliver an even stronger therapeutic effect, as suggested by data from patients with moderate psoriasis in the 200mg cohort of the completed Phase 2a trial.
Note “Forward-Looking Statements” below
Cellceutix issued the following press release on September 13, 2016
Cellceutix Corporation Provides Business Update and Timeline of Upcoming Milestones
BEVERLY, MA--(September 13, 2016) - Cellceutix Corporation (OTCQB: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, antibiotic, and anti-inflammatory applications, today provided a fiscal year-end business update including a timeline of key upcoming milestones.
Leo Ehrlich, Chief Executive Officer, commented, “We are extremely pleased with the tremendous progress that we have made, especially within the last 12 months. We have assembled an attractive portfolio of three unique compounds, each of which addresses very large markets and is supported by strong IP protection. To date, we have met all of the primary endpoints in each of our clinical trials, and we have a number of very important milestones upcoming during the course of the next 12 to 18 months. Many of these milestones have the potential to create a substantial inflection (turning) point in our market cap.”
Upcoming Milestones
Drug Candidate Event Description Period Year
Brilacidin Kevetrin Prurisol
X Clinical Update Ulcerative Proctitis- Interim analysis Ph2a trial 4Q 2016
X Trial Progress Ovarian Cancer- Initiation Ph2a trial 4Q 2016
X Trial Progress Psoriasis- Initiation Ph2b trial 4Q 2016
X Clinical Update Oral Mucositis- Interim analysis Ph2 1H 2017
X Clinical Update Psoriasis- Interim Analysis Ph2b 1H 2017
X Clinical Update Ulcerative Proctitis- Complete Ph2a trial 1H 2017
X Clinical Update Oral Mucositis- Complete analysis Ph2 trial 2H 2017
X Clinical Update Ovarian Cancer- PoC p53 modulation (Ph2a) 2H 2017
X Trial Progress ABSSSI- Start Ph3 trial * 2017 *Timetable dependent on reaching SPA agreement with FDA
Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Cellceutix, commented, “We are making progress advancing Prurisol through the clinical pathway. We completed a Phase 2a trial of Prurisol in patients with mild-to-moderate chronic plaque psoriasis in May 2016. The trial successfully achieved its primary endpoint, further validating Prurisol’s potential as a novel oral treatment for psoriasis. On the heels of these data, we are now planning our Phase 2b trial of Prurisol for patients with moderate-to-severe plaque psoriasis in order to better define appropriate dosing to achieve greatest clinical responses and we expect to have our interim analysis top-line results in the second quarter of 2017. We believe that the potential safety profile of Prurisol may make this an attractive alternative to Celgene’s OTEZLA, which is on its way to achieving $1 billion in sales within just three years of its launch.”
“We are also making headway with our Kevetrin asset, which has shown potent anti-tumor activity. Following our Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, we are now preparing for a Phase 2a trial of Kevetrin for treating late stage ovarian cancer. We anticipate that this trial will start in the fourth quarter of this year. Our plan is to conduct a small trial that will provide the critical data necessary to forge a partnership with a large pharmaceutical company that could potentially fund development of Kevetrin through FDA approval. We are encouraged by the guidance and feedback that we have received from potential partners which are incorporated in our Phase 2a trial design.”
“Lastly, we completed our Phase 2b trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI, and are moving forward with our Phase 2 clinical trial with Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin has a novel mechanism of action-- robust anti-bacterial as well as anti-inflammatory properties. In fact, a single dose of Brilacidin has been shown to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Moreover, we believe that it will demonstrate a broad spectrum of activity in infectious diseases, gastrointestinal and inflammatory diseases, and a variety of dermatological diseases.”
Mr. Ehrlich concluded, “To wrap up, the consistent theme across all of our compounds is strong supporting clinical data and a clear path to delivering a meaningful return on investment. We had previously been largely under the radar of Wall Street and institutional investors, but given our success to-date, we are now engaging in a much more aggressive outreach effort. We have a number of important upcoming milestones, that if successful, we believe will drive meaningful value for shareholders.”
About Cellceutix
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its plans for a Phase 2 study. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol completed a Phase 2 trial and Cellceutix is now setting up a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com.
Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning projected timelines for the initiation and completion of clinical trials, our future drug development plans, other statements regarding future product developments, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause Cellceutix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Cellceutix has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Cellceutix's need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that Cellceutix's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in Cellceutix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
Copyright © 2016 Cellceutix Corporation, All rights reserved.
You requested to receive email alerts about Cellceutix at our website www.cellceutix.com
Our mailing address is:
Cellceutix Corporation
100 Cummings Center, Suite 151-BBeverly, MA 01915
Add us to your address book
unsubscribe from this list | update subscription preferences
I'm not a finance guy, but any thoughts on this?...
Seadrill Partners' term loan B lenders intend to advocate for minimum cash leakage: http://ow.ly/P6Ku303oNLo . $SDLP
What?!?! It rapidly accelerated from $1.36 to the day's high of $1.39 right around 1:20 pm!!
What were you expecting? :)
Oh, let me add...IMO
I just talked to a source that heard from a relative who got a text from a cousin who got a FB message from her sister's fiancé that works for CTIX sales department that the stock should start its rapid accent this Wednesday around 1pm.
And if you look at Seres, insiders executed stock options at the high and then today, they release bad results and the stock tanks 75%. That should be investigated. No insider selling here!
CVRR just reported an earnings and revenue beat, but no distribution. Stock up 3% pre market.
Should ALDW report a beat AND a distribution after the close, I would imagine a great trading day tomorrow.
??
• CVR Refining (NYSE:CVRR): Q2 EPS of $0.53
• Revenue of $1.16B (-25.2% Y/Y) beats by $100M.
But no distribution!
http://seekingalpha.com/pr/16561172-cvr-refining-reports-2016-second-quarter-results
Dividend cut to 10 cents. Wonder if this stock will hold $5 today!?
I'll be in your area in December!! Can't wait. And who knows where CTIX will be at that time. Exiting times.
I think the answer to your question, as well as the answer to most questions on this board, is don't know, don't care.
It seems this board has become an I know better than management campaign and way too negative.
Dr. B hasn't been onboard for a week yet and already he is getting comments he doesn't know what he is doing. Am I happy B is delayed??? Of course not! But I am willing to be patient and see where our new President takes us. Plus we still have P, B-UP and B-OM. A lot to be excited about!
I think some were expecting us to be double digits by now and complaining. The share price will rise as long as the science continues to progress. Since it is, I continue to hold and wait and enjoy life. I believe Warren Buffett said it best...the stock market is an investment device to transfer wealth from the impatient to the patient.
Anybody have speculation to this PR...
Source: PR Newswire (US)
DALLAS, July 11, 2016 /PRNewswire/ -- As noted in the Alon USA Energy, Inc. (NYSE: ALJ) ("Alon") proxy statement, filed with the SEC on April 1, 2016, Alon's Board of Directors has formed a Special Committee (the "Special Committee"). The Special Committee is comprised of directors having no affiliation with Delek US Holdings, Inc. ("Delek"). Since its formation, the Special Committee has reviewed a number of strategic alternatives, a potential business combination with Delek, the analysis of capital investments, shareholder distributions, a sale or merger and a spin-off or separation of a selected business.
The Special Committee has set no timetable for the strategic review process and has not made a decision to pursue any particular transaction, and there can be no assurance that any transaction will be approved or consummated. Alon does not intend to disclose or comment on further developments regarding the review of strategic alternatives until it determines that such disclosure or comment is appropriate or necessary.
The Special Committee has retained J.P. Morgan as its financial advisor and Gibson Dunn as its legal advisor to assist in the assessment of strategic alternatives.
...merger? Acquisition? Special distribution? Influx of capital?
I'm not so sure...
The costs of compliance with the Exchange Act regulatory scheme can be prohibitively expensive for issuers with smaller capitalizations and start-ups that have limited financial resources. The OTC Pink Market (also known as the Pink Sheets) offers another option for public trading for issuers that are not required to have a class of securities registered under the Exchange Act, as securities can be quoted on the Pink Sheets without being registered under the Exchange Act. The Pink Sheets can offer access to the public securities markets without subjecting the issuer to compliance with the disclosure and reporting obligations and corporate governance requirements under the Exchange Act and the Sarbanes-Oxley Act.
An issuer that currently has a class of securities registered under Section 12(g) of the Exchange Act is generally permitted to deregister if there are fewer than 300 holders of record of the class of securities, or if there are fewer than 500 holders of such securities and the issuer’s total assets have not exceeded $10 million on the last day of its last three fiscal years. After an issuer deregisters under the Exchange Act and delists its securities from any national securities exchange on which they were listed, the issuer can apply for quotation on the Pink Sheets.
An issuer is not required to disclose any information as a condition to having its securities quoted on the Pink Sheets. However, the federal securities laws require issuers to provide adequate current public information in certain circumstances (for example, for the safe harbor provided by Rule 144 of the Securities Act of 1933 for resales of securities in the public markets[1], which applies regardless of whether the issuer’s securities are registered under the Exchange Act). In addition, regular disclosure of financial and operating results and other material events is important for transparency and maintaining the trust and confidence of security holders, regardless of whether such disclosure is required by law (the OTC warns investors that publicly traded companies that do not provide adequate current public information are highly risky and should be treated with suspicion). Furthermore, an issuer that deregisters under the Exchange Act in order to be quoted on the OTC Markets is likely to experience a decline in the trading price of its securities because the issuer is no longer subject to the Exchange Act’s rigorous disclosure requirements. The issuer can mitigate the decline by continuing to make adequate current public information available.
http://www.njcorporatelaw.com/benefits-of-quotation-on-the-otc-markets-in-lieu-of-exchange-act-registration/
Holy crazy last 15 minutes of trading!!
Another upgrade today...Wunderlich upgrades NGL to buy and $20 target price!!
http://www.americanbankingnews.com/2016/06/13/ngl-energy-partners-lp-ngl-rating-increased-to-buy-at-wunderlich/